NDASUBCUTANEOUSSOLUTION
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
ZEGALOGUE (dasiglucagon) by Zealand Pharma is glucagon receptor agonists [moa]. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEGALOGUE (dasiglucagon) is a glucagon receptor agonist administered subcutaneously to treat severe hypoglycemia in patients with diabetes. It rapidly raises blood glucose by activating hepatic glucagon receptors, mimicking the body's natural glucose-raising response. This rapid-acting formulation offers an alternative to traditional glucagon emergency kits.
Peak8.5 years to LOE
Product is in peak commercial phase with strong patent protection through 2035, indicating stable team sizing and continued investment in field force execution.
Mechanism of Action
Glucagon Receptor Agonists
Pharmacologic Class:
Antihypoglycemic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
Started Sep 2024
38 enrolled
Diabetes Mellitus, Type 1
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
Started May 2023
8 enrolled
HypoglycemiaType 1 Diabetes
Career Relevance
Working on ZEGALOGUE positions professionals in a peak-stage commercial environment with strong patent protection and stable market positioning through 2035. Roles focus on field execution, market access, and physician adoption rather than pipeline development or regulatory activities.
Worked on ZEGALOGUE at Zealand Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.